Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial.

Abstract:

Importance:Atabecestat, a nonselective oral β-secretase inhibitor, was evaluated in the EARLY trial for slowing cognitive decline in participants with preclinical Alzheimer disease. Preliminary analyses suggested dose-related cognitive worsening and neuropsychiatric adverse events (AEs). Objective:To report efficacy, safety, and biomarker findings in the EARLY trial, both on and off atabecestat treatment, with focus on potential recovery of effects on cognition and behavior. Design, Setting, and Participants:Randomized, double-blind, placebo-controlled, phase 2b/3 study conducted from November 2015 to December 2018 after being stopped prematurely. The study was conducted at 143 centers across 14 countries. Participants were permitted to be followed off-treatment by the original protocol, collecting safety and efficacy data. From 4464 screened participants, 557 amyloid-positive, cognitively normal (Clinical Dementia Rating of 0; aged 60-85 years) participants (approximately 34% of originally planned 1650) were randomized before the trial sponsor stopped enrollment. Interventions:Participants were randomized (1:1:1) to atabecestat, 5 mg (n = 189), 25 mg (n = 183), or placebo (n = 185). Main Outcomes and Measures:Primary outcome: change from baseline in Preclinical Alzheimer Cognitive Composite score. Secondary outcomes: change from baseline in the Cognitive Function Index and the Repeatable Battery for the Assessment of Neuropsychological Status total scale score. Safety was monitored throughout the study. Results:Of 557 participants, 341 were women (61.2%); mean (SD) age was 70.4 (5.56) years. In May 2018, study medication was stopped early owing to hepatic-related AEs; participants were followed up off-treatment for 6 months. Atabecestat, 25 mg, showed significant cognitive worsening vs placebo for Preclinical Alzheimer Cognitive Composite at month 6 (least-square mean difference, -1.09; 95% CI, -1.66 to -0.53; P < .001) and month 12 (least-square mean, -1.62; 95% CI, -2.49 to -0.76; P < .001), and at month 3 for Repeatable Battery for the Assessment of Neuropsychological Status (least-square mean, -3.70; 95% CI, -5.76 to -1.63; P < .001). Cognitive Function Index participant report showed nonsignificant worsening at month 12. Systemic and neuropsychiatric-related treatment-emergent AEs were greater in atabecestat groups vs placebo. After stopping treatment, follow-up cognitive testing and AE assessment provided evidence of reversibility of drug-induced cognitive worsening and AEs in atabecestat groups. Conclusions and Relevance:Atabecestat treatment was associated with dose-related cognitive worsening as early as 3 months and presence of neuropsychiatric treatment-emergent AEs, with evidence of reversibility after 6 months off treatment. Trial Registration:ClinicalTrials.gov Identifier: NCT02569398.

journal_name

JAMA Neurol

journal_title

JAMA neurology

authors

Sperling R,Henley D,Aisen PS,Raman R,Donohue MC,Ernstrom K,Rafii MS,Streffer J,Shi Y,Karcher K,Raghavan N,Tymofyeyev Y,Bogert J,Brashear HR,Novak G,Thipphawong J,Saad ZS,Kolb H,Rofael H,Sanga P,Romano G

doi

10.1001/jamaneurol.2020.4857

subject

Has Abstract

pub_date

2021-01-19 00:00:00

eissn

2168-6149

issn

2168-6157

pii

2774863

pub_type

杂志文章
  • Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study.

    abstract:IMPORTANCE:This dose-blinded extension of the phase 2 BOLD (BAF312 on MRI Lesion Given Once Daily) Study in relapsing-remitting multiple sclerosis provides evidence on disease activity and safety of a range of siponimod doses for up to 24 months. OBJECTIVE:To assess the safety and efficacy of siponimod for up to 24 mo...

    journal_title:JAMA neurology

    pub_type: 杂志文章,随机对照试验

    doi:10.1001/jamaneurol.2016.1451

    authors: Kappos L,Li DK,Stüve O,Hartung HP,Freedman MS,Hemmer B,Rieckmann P,Montalban X,Ziemssen T,Hunter B,Arnould S,Wallström E,Selmaj K

    更新日期:2016-09-01 00:00:00

  • Safety and Efficacy of Atorvastatin for Chronic Subdural Hematoma in Chinese Patients: A Randomized ClinicalTrial.

    abstract:Importance:Chronic subdural hematoma (CSDH) is a trauma-associated condition commonly found in elderly patients. Surgery is currently the treatment of choice, but it carries a significant risk of recurrence and death. Nonsurgical treatments remain limited and ineffective. Our recent studies suggest that atorvastatin re...

    journal_title:JAMA neurology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1001/jamaneurol.2018.2030

    authors: Jiang R,Zhao S,Wang R,Feng H,Zhang J,Li X,Mao Y,Yuan X,Fei Z,Zhao Y,Yu X,Poon WS,Zhu X,Liu N,Kang D,Sun T,Jiao B,Liu X,Yu R,Zhang J,Gao G,Hao J,Su N,Yin G,Zhu X,Lu Y,Wei J,Hu J,Hu R,Li J,Wang D

    更新日期:2018-11-01 00:00:00

  • Two Paradigms for Endovascular Thrombectomy After Intravenous Thrombolysis for Acute Ischemic Stroke.

    abstract:Importance:Intravenous thrombolysis (IVT) followed by mechanical thrombectomy (MT) is recommended to treat acute ischemic stroke (AIS) with a large vessel occlusion (LVO). Most hospitals do not have on-site MT facilities, and most patients need to be transferred secondarily after IVT (drip and ship), which may have an ...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2016.5823

    authors: Gerschenfeld G,Muresan IP,Blanc R,Obadia M,Abrivard M,Piotin M,Alamowitch S

    更新日期:2017-05-01 00:00:00

  • Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.

    abstract:Importance:Although levodopa remains the most effective oral pharmacotherapy for Parkinson disease (PD), its use is often limited by wearing off effect and dyskinesias. Management of such complications continues to be a significant challenge. Objective:To investigate the efficacy and safety of safinamide (an oral amin...

    journal_title:JAMA neurology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1001/jamaneurol.2016.4467

    authors: Schapira AH,Fox SH,Hauser RA,Jankovic J,Jost WH,Kenney C,Kulisevsky J,Pahwa R,Poewe W,Anand R

    更新日期:2017-02-01 00:00:00

  • New subtype of spinocerebellar ataxia with altered vertical eye movements mapping to chromosome 1p32.

    abstract:IMPORTANCE:To provide clinical and genetic diagnoses for patients' conditions, it is important to identify and characterize the different subtypes of spinocerebellar ataxia (SCA). OBJECTIVE:To clinically and genetically characterize a Spanish kindred with pure SCA presenting with altered vertical eye movements. DESIGN...

    journal_title:JAMA neurology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaneurol.2013.2311

    authors: Serrano-Munuera C,Corral-Juan M,Stevanin G,San Nicolás H,Roig C,Corral J,Campos B,de Jorge L,Morcillo-Suárez C,Navarro A,Forlani S,Durr A,Kulisevsky J,Brice A,Sánchez I,Volpini V,Matilla-Dueñas A

    更新日期:2013-06-01 00:00:00

  • Swiss cheese striatum: clinical implications.

    abstract:IMPORTANCE:Markedly enlarged Virchow-Robin spaces throughout the striatum appear occasionally on magnetic resonance imaging (MRI) scans of the elderly, and this type of striatum is known as the Swiss cheese striatum (SCS); however, its clinical impact is unknown. OBJECTIVE:To determine the clinical features associated...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2014.286

    authors: Burnett MS,Witte RJ,Ahlskog JE

    更新日期:2014-06-01 00:00:00

  • SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy.

    abstract:BACKGROUND:Therapies designed to decrease the level of SOD1 are currently in a clinical trial for patients with superoxide dismutase (SOD1)-linked familial amyotrophic lateral sclerosis (ALS). OBJECTIVE:To determine whether the SOD1 protein in cerebral spinal fluid (CSF) may be a pharmacodynamic marker for antisense o...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2013.593

    authors: Winer L,Srinivasan D,Chun S,Lacomis D,Jaffa M,Fagan A,Holtzman DM,Wancewicz E,Bennett CF,Bowser R,Cudkowicz M,Miller TM

    更新日期:2013-02-01 00:00:00

  • Current Concepts in Diagnosis and Treatment of Functional Neurological Disorders.

    abstract:Importance:Functional neurological disorders (FND) are common sources of disability in medicine. Patients have often been misdiagnosed, correctly diagnosed after lengthy delays, and/or subjected to poorly delivered diagnoses that prevent diagnostic understanding and lead to inappropriate treatments, iatrogenic harm, un...

    journal_title:JAMA neurology

    pub_type: 杂志文章,评审

    doi:10.1001/jamaneurol.2018.1264

    authors: Espay AJ,Aybek S,Carson A,Edwards MJ,Goldstein LH,Hallett M,LaFaver K,LaFrance WC Jr,Lang AE,Nicholson T,Nielsen G,Reuber M,Voon V,Stone J,Morgante F

    更新日期:2018-09-01 00:00:00

  • Characterization of Gene Expression Phenotype in Amyotrophic Lateral Sclerosis Monocytes.

    abstract:Importance:Amyotrophic lateral sclerosis (ALS) is a common adult-onset neurodegenerative disease characterized by selective loss of upper and lower motor neurons. Patients with ALS have persistent peripheral and central inflammatory responses including abnormally functioning T cells and activated microglia. However, mu...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2017.0357

    authors: Zhao W,Beers DR,Hooten KG,Sieglaff DH,Zhang A,Kalyana-Sundaram S,Traini CM,Halsey WS,Hughes AM,Sathe GM,Livi GP,Fan GH,Appel SH

    更新日期:2017-06-01 00:00:00

  • A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes.

    abstract:Importance:Cerebrospinal fluid (CSF) core Alzheimer disease (AD) biomarkers have shown an excellent capacity for the in vivo detection of AD. Previous studies have shown that CSF levels of phosphorylated tau (p-tau) also correlate with tau pathology in frontotemporal lobar degeneration (FTLD) after accounting for AD co...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2018.0118

    authors: Lleó A,Irwin DJ,Illán-Gala I,McMillan CT,Wolk DA,Lee EB,Van Deerlin VM,Shaw LM,Trojanowski JQ,Grossman M

    更新日期:2018-06-01 00:00:00

  • Multiple system atrophy and amyotrophic lateral sclerosis in a family with hexanucleotide repeat expansions in C9orf72.

    abstract:IMPORTANCE:Here we report a family with coexistence of multiple system atrophy (MSA) and amyotrophic lateral sclerosis (ALS) with hexanucleotide repeat expansions in C9orf72. OBSERVATIONS:A 65-year-old woman had a 2-year history of ataxia with autonomic dysfunction but without motor neuron signs. She was diagnosed as ...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2013.5762

    authors: Goldman JS,Quinzii C,Dunning-Broadbent J,Waters C,Mitsumoto H,Brannagan TH 3rd,Cosentino S,Huey ED,Nagy P,Kuo SH

    更新日期:2014-06-01 00:00:00

  • The growth and impact of Alzheimer disease centers as measured by social network analysis.

    abstract:IMPORTANCE:Alzheimer disease (AD) is a neurodegenerative disorder with no effective therapies. In 1984, the National Institute on Aging created the first 5 AD centers (ADCs) in an effort to coordinate research efforts into the pathology and treatment of the disease. Since that time, the ADC program has expanded to incl...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2013.6225

    authors: Hughes ME,Peeler J,Hogenesch JB,Trojanowski JQ

    更新日期:2014-04-01 00:00:00

  • Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder.

    abstract:IMPORTANCE:Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune inflammatory disorder of the central nervous system. Recently, various immunosuppressant medications were introduced as therapeutic options for preventing relapse of NMOSD. However, our understanding of the effectiveness of mycophenolate mofetil...

    journal_title:JAMA neurology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaneurol.2014.2057

    authors: Huh SY,Kim SH,Hyun JW,Joung AR,Park MS,Kim BJ,Kim HJ

    更新日期:2014-11-01 00:00:00

  • Association of CAG Repeats With Long-term Progression in Huntington Disease.

    abstract:Importance:In Huntington disease (HD), mutation severity is defined by the length of the CAG trinucleotide sequence, a well-known predictor of clinical onset age. The association with disease trajectory is less well characterized. Quantifiable summary measures of trajectory applicable over decades of early disease prog...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2019.2368

    authors: Langbehn DR,Stout JC,Gregory S,Mills JA,Durr A,Leavitt BR,Roos RAC,Long JD,Owen G,Johnson HJ,Borowsky B,Craufurd D,Reilmann R,Landwehrmeyer GB,Scahill RI,Tabrizi SJ,TRACK-HD and Track-On HD Groups.

    更新日期:2019-08-12 00:00:00

  • Hereditary ataxia and spastic paraplegia in Portugal: a population-based prevalence study.

    abstract:IMPORTANCE:Epidemiological data on hereditary cerebellar ataxia (HCA) and hereditary spastic paraplegia (HSP) are scarce. OBJECTIVE:To present the prevalence and distribution of HCA and HSP in Portugal. DESIGN AND SETTING:Population-based, nationwide, systematic survey, from January 1, 1994, through April 15, 2004, i...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2013.1707

    authors: Coutinho P,Ruano L,Loureiro JL,Cruz VT,Barros J,Tuna A,Barbot C,Guimarães J,Alonso I,Silveira I,Sequeiros J,Marques Neves J,Serrano P,Silva MC

    更新日期:2013-06-01 00:00:00

  • Blood pressure and progression of brain atrophy: the SMART-MR Study.

    abstract:IMPORTANCE:Studies have shown that both high and low blood pressure (BP) may play a role in the etiology of brain atrophy. High BP in midlife has been associated with more brain atrophy later in life, whereas studies in older populations have shown a relation between low BP and more brain atrophy. Yet, prospective evid...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2013.217

    authors: Jochemsen HM,Muller M,Visseren FL,Scheltens P,Vincken KL,Mali WP,van der Graaf Y,Geerlings MI,SMART Study Group.

    更新日期:2013-08-01 00:00:00

  • Risk of Symptomatic Intracerebral Hemorrhage After Intravenous Thrombolysis in Patients With Acute Ischemic Stroke and High Cerebral Microbleed Burden: A Meta-analysis.

    abstract:IMPORTANCE:Cerebral microbleeds (CMBs) have been established as an independent predictor of cerebral bleeding. There are contradictory data regarding the potential association of CMB burden with the risk of symptomatic intracerebral hemorrhage (sICH) in patients with acute ischemic stroke (AIS) treated with intravenous...

    journal_title:JAMA neurology

    pub_type: 杂志文章,meta分析

    doi:10.1001/jamaneurol.2016.0292

    authors: Tsivgoulis G,Zand R,Katsanos AH,Turc G,Nolte CH,Jung S,Cordonnier C,Fiebach JB,Scheitz JF,Klinger-Gratz PP,Oppenheim C,Goyal N,Safouris A,Mattle HP,Alexandrov AW,Schellinger PD,Alexandrov AV

    更新日期:2016-06-01 00:00:00

  • Sex and Race Differences in the Association of Incident Ischemic Stroke With Risk Factors.

    abstract:Importance:Race-specific and sex-specific stroke risk varies across the lifespan, yet few reports describe sex differences in stroke risk separately in black individuals and white individuals. Objective:To examine incidence and risk factors for ischemic stroke by sex for black and white individuals. Design, Setting, ...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2018.3862

    authors: Howard VJ,Madsen TE,Kleindorfer DO,Judd SE,Rhodes JD,Soliman EZ,Kissela BM,Safford MM,Moy CS,McClure LA,Howard G,Cushman M

    更新日期:2019-02-01 00:00:00

  • Serum Neurofilament Light Chain for Prognosis of Outcome After Cardiac Arrest.

    abstract:Importance:Prognostication of neurologic outcome after cardiac arrest is an important but challenging aspect of patient therapy management in critical care units. Objective:To determine whether serum neurofilament light chain (NFL) levels can be used for prognostication of neurologic outcome after cardiac arrest. Des...

    journal_title:JAMA neurology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaneurol.2018.3223

    authors: Moseby-Knappe M,Mattsson N,Nielsen N,Zetterberg H,Blennow K,Dankiewicz J,Dragancea I,Friberg H,Lilja G,Insel PS,Rylander C,Westhall E,Kjaergaard J,Wise MP,Hassager C,Kuiper MA,Stammet P,Wanscher MCJ,Wetterslev J,Erl

    更新日期:2019-01-01 00:00:00

  • Development of Expert-Level Automated Detection of Epileptiform Discharges During Electroencephalogram Interpretation.

    abstract:Importance:Interictal epileptiform discharges (IEDs) in electroencephalograms (EEGs) are a biomarker of epilepsy, seizure risk, and clinical decline. However, there is a scarcity of experts qualified to interpret EEG results. Prior attempts to automate IED detection have been limited by small samples and have not demon...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2019.3485

    authors: Jing J,Sun H,Kim JA,Herlopian A,Karakis I,Ng M,Halford JJ,Maus D,Chan F,Dolatshahi M,Muniz C,Chu C,Sacca V,Pathmanathan J,Ge W,Dauwels J,Lam A,Cole AJ,Cash SS,Westover MB

    更新日期:2020-01-01 00:00:00

  • Identifying Non-Duchenne Muscular Dystrophy-Positive and False Negative Results in Prior Duchenne Muscular Dystrophy Newborn Screening Programs: A Review.

    abstract:IMPORTANCE:Duchenne muscular dystrophy (DMD) is a candidate for the recommended universal screening panel based on evidence that early corticosteroid treatment improves outcomes and on new genetic therapies that require early diagnosis for effectiveness. Elevated creatine kinase levels in the neonatal period are the in...

    journal_title:JAMA neurology

    pub_type: 杂志文章,评审

    doi:10.1001/jamaneurol.2015.3537

    authors: Gatheridge MA,Kwon JM,Mendell JM,Scheuerbrandt G,Moat SJ,Eyskens F,Rockman-Greenberg C,Drousiotou A,Griggs RC

    更新日期:2016-01-01 00:00:00

  • Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial.

    abstract:Importance:Galcanezumab (LY2951742), a monoclonal antibody against calcitonin gene-related peptide (CGRP), is one of a novel class of new medicines for migraine prevention. Objective:To assess whether at least 1 dose of galcanezumab was superior to placebo for episodic migraine prevention. Design, Setting, and Partic...

    journal_title:JAMA neurology

    pub_type: 杂志文章,随机对照试验

    doi:10.1001/jamaneurol.2017.3859

    authors: Skljarevski V,Oakes TM,Zhang Q,Ferguson MB,Martinez J,Camporeale A,Johnson KW,Shan Q,Carter J,Schacht A,Goadsby PJ,Dodick DW

    更新日期:2018-02-01 00:00:00

  • The aging brain and cognition: contribution of vascular injury and aβ to mild cognitive dysfunction.

    abstract:IMPORTANCE:β-Amyloid (Aβ) deposition and vascular brain injury (VBI) frequently co-occur and are both associated with cognitive decline in aging. Determining whether a direct relationship exists between them has been challenging. We sought to understand VBI's influence on cognition and clinical impairment, separate fro...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/2013.jamaneurol.405

    authors: Marchant NL,Reed BR,Sanossian N,Madison CM,Kriger S,Dhada R,Mack WJ,DeCarli C,Weiner MW,Mungas DM,Chui HC,Jagust WJ

    更新日期:2013-04-01 00:00:00

  • Feasibility, Safety, and Outcome of Endovascular Recanalization in Childhood Stroke: The Save ChildS Study.

    abstract:Importance:Randomized clinical trials have shown the efficacy of thrombectomy of large intracranial vessel occlusions in adults; however, any association of therapy with clinical outcomes in children is unknown. Objective:To evaluate the use of endovascular recanalization in pediatric patients with arterial ischemic s...

    journal_title:JAMA neurology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaneurol.2019.3403

    authors: Sporns PB,Sträter R,Minnerup J,Wiendl H,Hanning U,Chapot R,Henkes H,Henkes E,Grams A,Dorn F,Nikoubashman O,Wiesmann M,Bier G,Weber A,Broocks G,Fiehler J,Brehm A,Psychogios M,Kaiser D,Yilmaz U,Morotti A,Marik W,

    更新日期:2020-01-01 00:00:00

  • Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment.

    abstract:Importance:The goal of preclinical Alzheimer disease (AD) clinical trials is to move diagnosis and treatment to presymptomatic stages, which will require biomarker testing and disclosure. Objective:To assess the short-term psychological outcomes of disclosing amyloid positron emission tomography results to older adult...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2020.2734

    authors: Grill JD,Raman R,Ernstrom K,Sultzer DL,Burns JM,Donohue MC,Johnson KA,Aisen PS,Sperling RA,Karlawish J,A4 Study Team.

    更新日期:2020-08-10 00:00:00

  • Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial.

    abstract:Importance:Doses of fingolimod lower than 0.5 mg per day were not investigated during the fingolimod clinical development program. Whether lower doses of fingolimod might retain efficacy with fewer safety risks remains unknown. Objective:To evaluate the efficacy and safety of fingolimod, 0.5 mg, and fingolimod, 0.25 m...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2020.2950

    authors: Cree BAC,Goldman MD,Corboy JR,Singer BA,Fox EJ,Arnold DL,Ford C,Weinstock-Guttman B,Bar-Or A,Mientus S,Sienkiewicz D,Zhang Y,Karan R,Tenenbaum N,ASSESS Trial Investigators.

    更新日期:2020-08-24 00:00:00

  • Association of Early-Onset Alzheimer Disease With Elevated Low-Density Lipoprotein Cholesterol Levels and Rare Genetic Coding Variants of APOB.

    abstract:Importance:Early-onset Alzheimer disease (EOAD) is a rare form of Alzheimer disease (AD) with a large genetic basis that is only partially understood. In late-onset AD, elevated circulating cholesterol levels increase AD risk even after adjusting for the apolipoprotein E ε4 (APOE E4) allele, a major genetic factor for ...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2019.0648

    authors: Wingo TS,Cutler DJ,Wingo AP,Le NA,Rabinovici GD,Miller BL,Lah JJ,Levey AI

    更新日期:2019-07-01 00:00:00

  • Association of pituitary adenylate cyclase-activating polypeptide with cognitive decline in mild cognitive impairment due to Alzheimer disease.

    abstract:IMPORTANCE:There is a deficit of pituitary adenylate cyclase-activating polypeptide (PACAP) in patients with neuropathologically confirmed Alzheimer dementia. However, whether this deficit is associated with the earlier stages of Alzheimer disease (AD) is unknown. This study was conducted to clarify the association bet...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2014.3625

    authors: Han P,Caselli RJ,Baxter L,Serrano G,Yin J,Beach TG,Reiman EM,Shi J

    更新日期:2015-03-01 00:00:00

  • Indirect measures of arterial stiffness and cognitive performance in individuals without traditional vascular risk factors or disease.

    abstract:IMPORTANCE:Whether cognition is influenced by arterial stiffness in the absence of vascular disease remains uncertain. OBJECTIVE:To test the hypotheses that indirect measures of arterial stiffness are important predictors of cognitive performance and that this relationship varies depending on the presence of vascular ...

    journal_title:JAMA neurology

    pub_type: 杂志文章

    doi:10.1001/jamaneurol.2014.3873

    authors: Gutierrez J,Marshall RS,Lazar RM

    更新日期:2015-03-01 00:00:00

  • Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome: A Randomized Clinical Trial.

    abstract:Importance:Basket-design clinical trials that allow investigation of treatment effects on different clinical syndromes that share the same molecular pathophysiology have not previously been attempted in neurodegenerative disease. Objective:To assess the safety, tolerability, and pharmacodynamics of the microtubule sta...

    journal_title:JAMA neurology

    pub_type: 杂志文章,随机对照试验

    doi:10.1001/jamaneurol.2019.3812

    authors: Tsai RM,Miller Z,Koestler M,Rojas JC,Ljubenkov PA,Rosen HJ,Rabinovici GD,Fagan AM,Cobigo Y,Brown JA,Jung JI,Hare E,Geldmacher DS,Natelson-Love M,McKinley EC,Luong PN,Chuu EL,Powers R,Mumford P,Wolf A,Wang P,Sham

    更新日期:2020-02-01 00:00:00